STERIS (STE) Q3 2026 earnings review
Resilient Growth Defies Tariff Headwinds
STERIS delivered a solid Q3 with 9% revenue growth and 9% Adjusted EPS growth, demonstrating the durability of its recurring revenue model despite a rising tariff bill. While the company maintained its full-year earnings guidance of $10.15-$10.30, it raised its estimated tariff impact to $55 million (up from $45 million). Operational strength in AST and Healthcare volume helped offset these costs, but Healthcare margins compressed as inflation and tariffs weighed on profitability. Cash flow remains a standout, with year-to-date free cash flow up 25%.
🐂 Bull Case
Year-to-date Free Cash Flow surged 25% to $737.6 million, driven by earnings growth and lower capital spending. The company is on track to hit ~$850 million for the full year, providing ample dry powder for M&A or buybacks.
The high-margin Service and Consumable businesses continue to drive the topline. Healthcare Service revenue grew 11% and Consumables grew 8%, insulating the company from capital equipment volatility.
🐻 Bear Case
Despite 9% revenue growth in the largest segment (Healthcare), operating income grew only 4.5%. Segment operating margins contracted 110 basis points to 24.2% as tariff costs and inflation outpaced pricing and productivity.
Management raised the estimated full-year pre-tax profit impact from tariffs to $55 million (previously $45 million). While guidance was maintained, this represents a growing headwind that is eating into operational upside.
⚖️ Verdict: 🟢
Stable. STERIS is effectively managing a difficult cost environment. While the margin compression in Healthcare is a concern, the ability to maintain full-year guidance despite a $10 million increase in tariff costs demonstrates operational resilience and pricing power.
Key Themes
Tariff Impact Worsens
The specific headwind from tariffs has intensified. The company now expects a $55 million hit to pre-tax profit for FY26, up from the $45 million guided in Q2. This effectively creates a ~$0.10 EPS drag that the company is absorbing through other efficiencies.
Life Sciences Recovery
The Life Sciences segment is stabilizing after a cyclical trough. Revenue grew 7% reported (5% organic), and notably, the backlog sits at $113.4 million—up 33% from $85.1 million a year ago. This elevated backlog suggests sustained demand for capital equipment in pharma manufacturing.
Healthcare Profitability Lag
Healthcare is growing top-line but struggling to convert it to bottom-line growth at the same rate. In Q3, revenue increased $87.8 million YoY, but operating income only increased $11.2 million. This 13% incremental conversion rate indicates that cost pressures (inflation/tariffs) are currently overwhelming operating leverage.
AST Service Strength
Applied Sterilization Technologies (AST) remains a high-margin grower. Segment revenue grew 11% (8% organic), driven by 9% growth in service revenue. Operating margin in this segment remains robust at ~45% ($129.2M income on $286.6M revenue), providing a critical profit anchor for the consolidated business.
Debt Reduction & Balance Sheet
With $737.6 million in YTD free cash flow, the company has increased its cash position to $423.7 million (up from $171.7M at year-start) while reducing short-term indebtedness to zero (from $125M). This deleveraging creates optionality for future capital deployment.
Other KPIs
Accelerating. Up 25% from $588.1 million in the prior year period. Driven by earnings growth and a reduction in capital spending ($278.8M vs $299.2M).
Stable. Up 9% YoY (8% organic). Service revenue (+11%) and Consumables (+8%) continue to outperform Capital Equipment (+7%).
Accelerating. Up 11% reported vs 9% last quarter. Constant currency organic growth was 8%.
Guidance
Decelerating. The maintained full-year range implies Q4 Adjusted EPS of ~$2.88 at the midpoint, which represents ~5% YoY growth. This is a deceleration from the 9% growth delivered in Q3 and 15% in H1.
Decelerating. With YTD revenue growth at 9.3%, the full-year guide implies Q4 revenue growth of ~6-8%, slowing slightly from the current run rate.
Stable. Guidance maintained. Implies Q4 FCF of ~$112 million, consistent with seasonal patterns and capital expenditure plans.
Accelerating (Negative). Increased from prior guide of $45 million. Represents a direct hit to profitability that management is working to offset.
Key Questions
Healthcare Margin Recovery
Healthcare operating margins compressed 110 basis points YoY despite 9% revenue growth. With tariff headwinds intensifying, what specific levers (pricing, cost cuts) are available to restore margin expansion in Q4 and FY27?
Tariff Mitigation Specifics
The tariff impact estimate rose by $10 million this quarter. Are these costs structural/permanent, or does the company have supply chain flexibility to mitigate this impact over the next 12 months?
Implied Q4 Deceleration
Guidance implies Q4 EPS growth slows to ~5% from 9% in Q3 and 15% in H1. Is this conservatism, or are there specific headwinds (e.g., timing of shipments, mix shift) expected to weigh on the final quarter?
AST Capital Equipment Spike
AST Capital Equipment revenue grew 103% YoY in Q3 (albeit off a small base). Is this a signal of a broader capacity expansion cycle among customers, and is it sustainable?